Compare Iovance Biotherapeutics Inc. Common Stock (IOVA) vs Nucor Corporation (NUE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Iovance Biotherapeutics Inc. Common Stock vs Nucor Corporation — how do they compare? Iovance Biotherapeutics Inc. Common Stock trades at $13.46 (market cap $6.04B), while Nucor Corporation trades at $248 (market cap $55.84B). The key difference: Nucor Corporation is far larger — about 9.2× Iovance Biotherapeutics Inc. Common Stock's market cap, and Nucor Corporation pays a 0.91% dividend while Iovance Biotherapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Iovance Biotherapeutics Inc. Common Stock for 0 Days and Nucor Corporation for 78 Days on average.
| IOVA | NUE | |
|---|---|---|
Market Cap | $6.04B | $55.84B |
Volume | 14,805,993 | 848,835 |
Sector | Health | Basic Materials |
52-Week High | $14.82 | $274.74 |
52-Week Low | $1.81 | $131.78 |
Typical Hold Time | 0 Days | 78 Days |
Enterprise Value | $5.97B | $60.25B |
Dividend Yield | — | 0.91% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Nucor (NUE) trades at $246.44, down 1.84% on the day, with mixed technical signals showing neutral momentum. The stock has demonstrated strong earnings performance with recent beats in Q1 and Q2 2026, though Q4 2025 missed expectations. Revenue has stabilized around $32.5B after declining from 2022 peaks, while profit margins show recovery signs. Analysts maintain a bullish stance with a $266.88 price target, representing 8% upside potential from current levels.
Nucor presents a balanced investment case with improving fundamentals but faces cyclical steel industry headwinds. The company's dividend king status and strong operational execution support long-term value, while competitive pressures and margin volatility remain key risks. Current valuation appears reasonable with P/E of 19.67 and P/S of 1.57, suggesting potential for moderate growth if steel demand strengthens.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Iovance Biotherapeutics Inc. Common Stock
Iovance Biotherapeutics develops cell therapies for cancer. Its approach uses tumor-infiltrating lymphocytes, or TIL, to target solid tumors.
Read more on IOVA →About Nucor Corporation
Nucor Corp manufactures steel and steel products. The company also produces direct reduced iron for use in its steel mills. The operations include international trading and sales companies that buy and sell steel and steel products manufactured by the company and others. The operating business segments are: steel mills, steel products and raw materials, the steel mills segment derives maximum revenue.
Read more on NUE →
